Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-17-005623
Filing Date
2017-05-19
Accepted
2017-05-19 15:12:14
Documents
57
Period of Report
2017-03-31

Document Format Files

Seq Description Document Type Size
1 form10-q.htm 10-Q 991295
2 ex31-1.htm EX-31.1 16657
3 ex31-2.htm EX-31.2 16301
4 ex32-1.htm EX-32.1 6984
5 ex32-2.htm EX-32.2 7546
  Complete submission text file 0001493152-17-005623.txt   6270080

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE FILE rspi-20170331.xml EX-101.INS 1089073
7 XBRL SCHEMA FILE rspi-20170331.xsd EX-101.SCH 84386
8 XBRL CALCULATION FILE rspi-20170331_cal.xml EX-101.CAL 43558
9 XBRL DEFINITION FILE rspi-20170331_def.xml EX-101.DEF 326091
10 XBRL LABEL FILE rspi-20170331_lab.xml EX-101.LAB 523457
11 XBRL PRESENTATION FILE rspi-20170331_pre.xml EX-101.PRE 379094
Mailing Address 126 VALLEY ROAD SUITE C GLEN ROCK NJ 07452
Business Address 126 VALLEY ROAD SUITE C GLEN ROCK NJ 07452 (201) 444-4947
RespireRx Pharmaceuticals Inc. (Filer) CIK: 0000849636 (see all company filings)

EIN.: 330303583 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-16467 | Film No.: 17857586
SIC: 2834 Pharmaceutical Preparations